[ad_1] HONG KONG, Dec. 10, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ivonescimab (a PD-1/VEGF bispecific […]
Tag: Clinical Trials & Medical Discoveries
Die Fondazione Telethon gibt die FDA-Zulassung von Waskyra™ (Etuvetidigene Autotemcel) bekannt, einer Gentherapie zur Behandlung des Wiskott-Aldrich-Syndroms USA – Deutsch USA – English USA – English Italia – Italiano USA – Français USA – español
[ad_1] WAS betrifft fast ausschließlich Männer, mit einer geschätzten Inzidenz von 1 zu 250.000 Lebensgeburten männlicher Kinder. Die Therapie stellt eine große wissenschaftliche und klinische Errungenschaft dar und gibt den betroffenen Patienten neue Hoffnung. ROM, […]
Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
[ad_1] – Data reflect new insights and precision oncology advancements in portfolio and pipeline – – Cohort results from Phase 2 ILUSTRO study evaluating a zolbetuximab triplet combination regimen in first-line advanced gastric and gastroesophageal […]
ECOG-ACRIN and Caris Life Sciences unveil first findings from a multi-year collaboration to advance AI-powered multimodal tools for breast cancer recurrence risk stratification
[ad_1] New AI models integrating imaging, clinical, and molecular data from the TAILORx tissue biorepository show stronger prognostic performance than current methods to predict recurrence risk in early-stage breast cancer and guide long-term treatment decisions […]
Privo Technologies Begins Dosing PRV131 in Arm 3 Of Clinical Study CLN-004, A First-In-Class Cisplatin Intratumoral Injectable Targeting Oral Cavity Cancer
[ad_1] Key Highlights: First-in-human milestone: The inaugural patient has been dosed with PRV131. Precise, localized delivery: Built on Privo’s PRV Platform technology, PRV131 delivers high concentrations of cisplatin directly to tumors, while minimizing systemic exposure. […]
